Raymond James Financial Inc. Sells 26,000 Shares of QIAGEN N.V. $QGEN

Key Points

• Raymond James Financial Inc. reduced its stake in Qiagen N.V. by 10.5% in Q1, holding 222,314 shares valued at approximately $8.93 million.
• Over 70% of Qiagen's stock is owned by institutional investors, with several funds, including Wealth Enhancement Advisory Services LLC and GAMMA Investing LLC, recently changing their positions.
• Qiagen reported a quarterly revenue increase of 7.7%, reaching $533.54 million, meeting analysts' expectations for earnings per share at $0.60.

Raymond James Financial Inc. cut its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 10.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 222,314 shares of the company's stock after selling 26,000 shares during the quarter. Raymond James Financial Inc. owned approximately 0.10% of QIAGEN worth $8,926,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Exchange Traded Concepts LLC raised its position in shares of QIAGEN by 2.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after buying an additional 395 shares in the last quarter. Cetera Investment Advisers raised its position in shares of QIAGEN by 14.4% during the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock worth $505,000 after buying an additional 1,418 shares in the last quarter. GAMMA Investing LLC raised its position in shares of QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after buying an additional 1,425 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of QIAGEN by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after buying an additional 2,204 shares in the last quarter. Finally, Avantax Advisory Services Inc. raised its position in shares of QIAGEN by 30.2% during the 1st quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company's stock worth $396,000 after buying an additional 2,290 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on QGEN shares. Bank of America boosted their price target on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. UBS Group boosted their target price on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Cowen reiterated a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Barclays began coverage on shares of QIAGEN in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price on the stock. Finally, Wall Street Zen downgraded shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, QIAGEN presently has an average rating of "Hold" and an average target price of $49.69.

QIAGEN Trading Up 1.1%

Shares of QGEN stock traded up $0.50 during trading hours on Friday, reaching $47.54. 939,634 shares of the stock traded hands, compared to its average volume of 1,350,406. QIAGEN N.V. has a 1-year low of $37.63 and a 1-year high of $51.88. The business has a fifty day moving average price of $48.65 and a 200 day moving average price of $44.35. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $10.57 billion, a PE ratio of 28.08, a PEG ratio of 2.48 and a beta of 0.64.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The firm's revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities research analysts forecast that QIAGEN N.V. will post 2.26 EPS for the current year.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.